Global Premature Ejaculation Market
Global Premature Ejaculation Market

Premature Ejaculation Comprehensive Study by Type (Lifelong (Primary), Acquired (Secondary)), Application (Hospitals, Clinics), Treatment (Medical Therapy, Non-Medical Therapy) Players and Region - Global Market Outlook to 2025

Premature Ejaculation Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Aug 2020 Edition 223 Pages 188 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Premature Ejaculation Market?

Premature ejaculation (PE) happens when a man regularly reaches an orgasm much sooner during sexual intercourse. The main sign of PE is incapability to delay ejaculation for more than one minute after penetration. Premature ejaculation can be due to anxiety and personal problems that cause stress. An individualís relationship with his partner can get affected due to such kind of problem. It can be classified as lifelong premature ejaculation and acquired premature ejaculation. The other factors which can cause premature ejaculation are swelling of prostate or urethra, inherited traits and abnormal levels of neurotransmitters.

The market study is being classified by Type (Lifelong [Primary] and Acquired [Secondary]), by Application (Hospitals and Clinics) and major geographies with country level break-up.

Absorption Pharmaceuticals (United States), Plethora Solutions Holdings (United Kingdom), Ixchelsis (United Kingdom), NeuroHealing Pharmaceuticals Inc. (United States), Regent Pacific Group Limited (Hong Kong), Furiex Pharmaceuticals Inc. (United States), The Menarini Group (Italy), Royalty Pharma (Switzerland), Premature ejaculation (Italy), GlaxoSmithKline (United Kingdom), Innovus Pharmaceutical (United States), Pfizer Inc. (United States) and Futura Medical GlaxoSmithKline (United Kingdom) are some of the key players profiled in the study.

The premature ejaculation treatment market is competitive. The players in the market are focusing on launching new products, which in turn is expected to aid in growth of the market. Vendors of the premature ejaculation treatment are increasingly competing against each other based on factors such as the quality, pricing, market reach, and financial resources. Research Analyst at AMA predicts that United States and United Kingdom Players will contribute to the maximum growth of Global Premature Ejaculation market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Premature Ejaculation market by Type, Application and Region.

On the basis of geography, the market of Premature Ejaculation has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing Patient Willingness to seek Pharmaceutical Therapy Assistance
  • Increasing Number of Patients Suffering with Premature Ejaculation Disorders

Market Trend
  • Increasing Awareness about Premature Ejaculation
  • Increasing Presence of Favorable Guidelines

Restraints
  • Introduction of Alternative Treatment Methods for Premature Ejaculation

Opportunities
  • Pharmaceutical Advances in PE Drug Formulation Technology

Challenges
  • Associated Adverse Effects of PE Drugs


Market Leaders and some development strategies
December 21, 2019: Recordati acquires Tonipharm S.A.S. in France. The acquisition of Tonipharm represents a further opportunity to enhance the portfolio of Recordati in French self-medication market with well-known brands and good market shares.



Key Target Audience
Suppliers of Premature Ejaculation Drug, Wholesalers, distributers and retailers of Premature Ejaculation Drug, Healthcare Industry, Research Firms and Governmental Bodies

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Lifelong [Primary]
  • Acquired [Secondary]
By Application
  • Hospitals
  • Clinics
By Treatment
  • Medical Therapy
  • Non-Medical Therapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Patient Willingness to seek Pharmaceutical Therapy Assistance
      • 3.2.2. Increasing Number of Patients Suffering with Premature Ejaculation Disorders
    • 3.3. Market Challenges
      • 3.3.1. Associated Adverse Effects of PE Drugs
    • 3.4. Market Trends
      • 3.4.1. Increasing Awareness about Premature Ejaculation
      • 3.4.2. Increasing Presence of Favorable Guidelines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Premature Ejaculation, by Type, Application, Treatment and Region (value and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Premature Ejaculation (Value)
      • 5.2.1. Global Premature Ejaculation by: Type (Value)
        • 5.2.1.1. Lifelong [Primary]
        • 5.2.1.2. Acquired [Secondary]
      • 5.2.2. Global Premature Ejaculation by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
      • 5.2.3. Global Premature Ejaculation by: Treatment (Value)
        • 5.2.3.1. Medical Therapy
        • 5.2.3.2. Non-Medical Therapy
      • 5.2.4. Global Premature Ejaculation Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Premature Ejaculation (Price)
      • 5.3.1. Global Premature Ejaculation by: Type (Price)
  • 6. Premature Ejaculation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Absorption Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Plethora Solutions Holdings (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ixchelsis (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. NeuroHealing Pharmaceuticals Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Regent Pacific Group Limited (Hong Kong)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Furiex Pharmaceuticals Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. The Menarini Group (Italy)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Royalty Pharma (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Premature ejaculation (Italy)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Innovus Pharmaceutical (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Pfizer Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Futura Medical GlaxoSmithKline (United Kingdom)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Premature Ejaculation Sale, by Type, Application, Treatment and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Premature Ejaculation (Value)
      • 7.2.1. Global Premature Ejaculation by: Type (Value)
        • 7.2.1.1. Lifelong [Primary]
        • 7.2.1.2. Acquired [Secondary]
      • 7.2.2. Global Premature Ejaculation by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
      • 7.2.3. Global Premature Ejaculation by: Treatment (Value)
        • 7.2.3.1. Medical Therapy
        • 7.2.3.2. Non-Medical Therapy
      • 7.2.4. Global Premature Ejaculation Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Premature Ejaculation (Price)
      • 7.3.1. Global Premature Ejaculation by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Premature Ejaculation: by Type(USD Million)
  • Table 2. Premature Ejaculation Lifelong [Primary] , by Region USD Million (2014-2019)
  • Table 3. Premature Ejaculation Acquired [Secondary] , by Region USD Million (2014-2019)
  • Table 4. Premature Ejaculation: by Application(USD Million)
  • Table 5. Premature Ejaculation Hospitals , by Region USD Million (2014-2019)
  • Table 6. Premature Ejaculation Clinics , by Region USD Million (2014-2019)
  • Table 7. Premature Ejaculation: by Treatment(USD Million)
  • Table 8. Premature Ejaculation Medical Therapy , by Region USD Million (2014-2019)
  • Table 9. Premature Ejaculation Non-Medical Therapy , by Region USD Million (2014-2019)
  • Table 10. South America Premature Ejaculation, by Country USD Million (2014-2019)
  • Table 11. South America Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 12. South America Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 13. South America Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 14. Brazil Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 15. Brazil Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 16. Brazil Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 17. Argentina Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 18. Argentina Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 19. Argentina Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 20. Rest of South America Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 21. Rest of South America Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 22. Rest of South America Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 23. Asia Pacific Premature Ejaculation, by Country USD Million (2014-2019)
  • Table 24. Asia Pacific Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 25. Asia Pacific Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 26. Asia Pacific Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 27. China Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 28. China Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 29. China Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 30. Japan Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 31. Japan Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 32. Japan Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 33. India Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 34. India Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 35. India Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 36. South Korea Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 37. South Korea Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 38. South Korea Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 39. Taiwan Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 40. Taiwan Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 41. Taiwan Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 42. Australia Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 43. Australia Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 44. Australia Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 45. Rest of Asia-Pacific Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 46. Rest of Asia-Pacific Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 47. Rest of Asia-Pacific Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 48. Europe Premature Ejaculation, by Country USD Million (2014-2019)
  • Table 49. Europe Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 50. Europe Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 51. Europe Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 52. Germany Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 53. Germany Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 54. Germany Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 55. France Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 56. France Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 57. France Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 58. Italy Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 59. Italy Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 60. Italy Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 61. United Kingdom Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 62. United Kingdom Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 63. United Kingdom Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 64. Netherlands Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 65. Netherlands Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 66. Netherlands Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 67. Rest of Europe Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 68. Rest of Europe Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 69. Rest of Europe Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 70. MEA Premature Ejaculation, by Country USD Million (2014-2019)
  • Table 71. MEA Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 72. MEA Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 73. MEA Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 74. Middle East Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 75. Middle East Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 76. Middle East Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 77. Africa Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 78. Africa Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 79. Africa Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 80. North America Premature Ejaculation, by Country USD Million (2014-2019)
  • Table 81. North America Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 82. North America Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 83. North America Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 84. United States Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 85. United States Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 86. United States Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 87. Canada Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 88. Canada Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 89. Canada Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 90. Mexico Premature Ejaculation, by Type USD Million (2014-2019)
  • Table 91. Mexico Premature Ejaculation, by Application USD Million (2014-2019)
  • Table 92. Mexico Premature Ejaculation, by Treatment USD Million (2014-2019)
  • Table 93. Premature Ejaculation: by Type(USD/Units)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Premature Ejaculation: by Type(USD Million)
  • Table 108. Premature Ejaculation Lifelong [Primary] , by Region USD Million (2020-2025)
  • Table 109. Premature Ejaculation Acquired [Secondary] , by Region USD Million (2020-2025)
  • Table 110. Premature Ejaculation: by Application(USD Million)
  • Table 111. Premature Ejaculation Hospitals , by Region USD Million (2020-2025)
  • Table 112. Premature Ejaculation Clinics , by Region USD Million (2020-2025)
  • Table 113. Premature Ejaculation: by Treatment(USD Million)
  • Table 114. Premature Ejaculation Medical Therapy , by Region USD Million (2020-2025)
  • Table 115. Premature Ejaculation Non-Medical Therapy , by Region USD Million (2020-2025)
  • Table 116. South America Premature Ejaculation, by Country USD Million (2020-2025)
  • Table 117. South America Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 118. South America Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 119. South America Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 120. Brazil Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 121. Brazil Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 122. Brazil Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 123. Argentina Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 124. Argentina Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 125. Argentina Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 126. Rest of South America Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 127. Rest of South America Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 128. Rest of South America Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 129. Asia Pacific Premature Ejaculation, by Country USD Million (2020-2025)
  • Table 130. Asia Pacific Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 131. Asia Pacific Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 132. Asia Pacific Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 133. China Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 134. China Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 135. China Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 136. Japan Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 137. Japan Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 138. Japan Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 139. India Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 140. India Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 141. India Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 142. South Korea Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 143. South Korea Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 144. South Korea Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 145. Taiwan Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 146. Taiwan Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 147. Taiwan Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 148. Australia Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 149. Australia Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 150. Australia Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 151. Rest of Asia-Pacific Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 152. Rest of Asia-Pacific Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 153. Rest of Asia-Pacific Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 154. Europe Premature Ejaculation, by Country USD Million (2020-2025)
  • Table 155. Europe Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 156. Europe Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 157. Europe Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 158. Germany Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 159. Germany Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 160. Germany Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 161. France Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 162. France Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 163. France Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 164. Italy Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 165. Italy Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 166. Italy Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 167. United Kingdom Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 168. United Kingdom Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 169. United Kingdom Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 170. Netherlands Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 171. Netherlands Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 172. Netherlands Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 173. Rest of Europe Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 174. Rest of Europe Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 175. Rest of Europe Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 176. MEA Premature Ejaculation, by Country USD Million (2020-2025)
  • Table 177. MEA Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 178. MEA Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 179. MEA Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 180. Middle East Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 181. Middle East Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 182. Middle East Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 183. Africa Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 184. Africa Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 185. Africa Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 186. North America Premature Ejaculation, by Country USD Million (2020-2025)
  • Table 187. North America Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 188. North America Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 189. North America Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 190. United States Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 191. United States Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 192. United States Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 193. Canada Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 194. Canada Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 195. Canada Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 196. Mexico Premature Ejaculation, by Type USD Million (2020-2025)
  • Table 197. Mexico Premature Ejaculation, by Application USD Million (2020-2025)
  • Table 198. Mexico Premature Ejaculation, by Treatment USD Million (2020-2025)
  • Table 199. Premature Ejaculation: by Type(USD/Units)
  • Table 200. Research Programs/Design for This Report
  • Table 201. Key Data Information from Secondary Sources
  • Table 202. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Premature Ejaculation: by Type USD Million (2014-2019)
  • Figure 5. Global Premature Ejaculation: by Application USD Million (2014-2019)
  • Figure 6. Global Premature Ejaculation: by Treatment USD Million (2014-2019)
  • Figure 7. South America Premature Ejaculation Share (%), by Country
  • Figure 8. Asia Pacific Premature Ejaculation Share (%), by Country
  • Figure 9. Europe Premature Ejaculation Share (%), by Country
  • Figure 10. MEA Premature Ejaculation Share (%), by Country
  • Figure 11. North America Premature Ejaculation Share (%), by Country
  • Figure 12. Global Premature Ejaculation: by Type USD/Units (2014-2019)
  • Figure 13. Global Premature Ejaculation share by Players 2019 (%)
  • Figure 14. Global Premature Ejaculation share by Players (Top 3) 2019(%)
  • Figure 15. Global Premature Ejaculation share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Absorption Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 18. Absorption Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 19. Plethora Solutions Holdings (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Plethora Solutions Holdings (United Kingdom) Revenue: by Geography 2019
  • Figure 21. Ixchelsis (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Ixchelsis (United Kingdom) Revenue: by Geography 2019
  • Figure 23. NeuroHealing Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. NeuroHealing Pharmaceuticals Inc. (United States) Revenue: by Geography 2019
  • Figure 25. Regent Pacific Group Limited (Hong Kong) Revenue, Net Income and Gross profit
  • Figure 26. Regent Pacific Group Limited (Hong Kong) Revenue: by Geography 2019
  • Figure 27. Furiex Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Furiex Pharmaceuticals Inc. (United States) Revenue: by Geography 2019
  • Figure 29. The Menarini Group (Italy) Revenue, Net Income and Gross profit
  • Figure 30. The Menarini Group (Italy) Revenue: by Geography 2019
  • Figure 31. Royalty Pharma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Royalty Pharma (Switzerland) Revenue: by Geography 2019
  • Figure 33. Premature ejaculation (Italy) Revenue, Net Income and Gross profit
  • Figure 34. Premature ejaculation (Italy) Revenue: by Geography 2019
  • Figure 35. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2019
  • Figure 37. Innovus Pharmaceutical (United States) Revenue, Net Income and Gross profit
  • Figure 38. Innovus Pharmaceutical (United States) Revenue: by Geography 2019
  • Figure 39. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 41. Futura Medical GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 42. Futura Medical GlaxoSmithKline (United Kingdom) Revenue: by Geography 2019
  • Figure 43. Global Premature Ejaculation: by Type USD Million (2020-2025)
  • Figure 44. Global Premature Ejaculation: by Application USD Million (2020-2025)
  • Figure 45. Global Premature Ejaculation: by Treatment USD Million (2020-2025)
  • Figure 46. South America Premature Ejaculation Share (%), by Country
  • Figure 47. Asia Pacific Premature Ejaculation Share (%), by Country
  • Figure 48. Europe Premature Ejaculation Share (%), by Country
  • Figure 49. MEA Premature Ejaculation Share (%), by Country
  • Figure 50. North America Premature Ejaculation Share (%), by Country
  • Figure 51. Global Premature Ejaculation: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Absorption Pharmaceuticals (United States)
  • Plethora Solutions Holdings (United Kingdom)
  • Ixchelsis (United Kingdom)
  • NeuroHealing Pharmaceuticals Inc. (United States)
  • Regent Pacific Group Limited (Hong Kong)
  • Furiex Pharmaceuticals Inc. (United States)
  • The Menarini Group (Italy)
  • Royalty Pharma (Switzerland)
  • Premature ejaculation (Italy)
  • GlaxoSmithKline (United Kingdom)
  • Innovus Pharmaceutical (United States)
  • Pfizer Inc. (United States)
  • Futura Medical GlaxoSmithKline (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation